Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Pfizer presents new sodium/glucose cotransporter 2 inhibitors

March 23, 2010

FDA issues warning for highest approved dose of cholesterol-lowering Zocor

March 22, 2010

Novel mu opioid receptor inverse agonist in phase I development by GSK for obesity

March 22, 2010

Takeda withdraws MAA for prolonged-release Competact for type 2 diabetes

March 22, 2010

Boehringer Ingelheim claims new Mnk1 and/or Mnk2 inhibitors

March 22, 2010

Boehringer Ingelheim presents novel 11-beta-HSD1 inhibitors

March 22, 2010

FDA approves Carbaglu for N-acetylglutamate synthase deficiency

March 19, 2010

CPEX presents preliminary phase IIa results of Nasulin in type 2 diabetes

March 19, 2010

FDA accepts for review NDA for fixed-dose Onglyza/metformin combination in type 2 diabetes

March 18, 2010

Hetero Research Foundation claims new sodium/glucose cotransporter 2 inhibitors

March 18, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.